News und Analysen
Agilent Introduces New Handheld Raw Material ID System for Pharmaceutical Manufacturers
Agilent Technologies Inc. (NYSE: A) today announced the launch of the newest instrument in its Raman technology portfolio. The new Agilent Vaya Raman raw material identity verification system is a
Epigenomics: US-Investoren zeichnen Aktien – jetzt rein?
Epigenomics (WKN: A11QW5) nimmt frisches Kapital auf. Dazu werden Aktien zu einem Preis von je 1,11 Euro bei Investoren platziert. Heute kommt die Bestätigung, dass institutionelle Investoren aus
Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navidea’s Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Bionomics and MSD Scientists Publish Preclinical Findings for BNC375 in Peer-Reviewed Journal
Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company, today announced that a paper describing the pharmacology of BNC375, a novel positive allosteric
QIAGEN Receives U.S. FDA EUA for QIAstat-Dx test kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its newly developed
QIAGEN erhält als erste und bisher einzige syndromische Testoption Notfallzulassung der FDA für QIAstat-Dx-Testpanel zum Nachweis des Coronavirus SARS-CoV-2
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass es von der US-amerikanischen Arzneimittelzulassungsbehörde FDA eine Notfallzulassung (Emergency Use Authorization) für
Sirona Biochem: Ein peinlicher Akt der Verzweiflung!
Die kanadische Schönheitsschmiede Sirona Biochem (WKN: A0RM6R) versucht, vom Corona-Hype zu profitieren. Tatsächlich springen einige Dummzocker darauf an. Das Unternehmen dürfte sich am Ende aber
Good News bei... Eckert & Ziegler: Rekordgewinn, Dividendenerhöhung und ein Aktiensplit
Update on 92nd Vifor Pharma Ltd. Annual General Meeting
Regulatory News:
Vifor Pharma confirmed that it will hold its Annual General Meeting (AGM) on 14 May, 2020, as planned. In view of the current situation and based on Art. 6a of Ordinance 2
Update zur 92. Generalversammlung der Vifor Pharma AG
Regulatory News:
Vifor Pharma hat bestätigt, dass die Generalversammlung des Unternehmens wie geplant am 14. Mai 2020 abgehalten wird. Aufgrund der aktuellen Situation und im Einklang mit Art. 6a
IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results
IMV Inc. (the “Company” or “IMV”) (TSX:IMV; NASDAQ:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational
Savara Provides Business Update in Response to COVID-19 Pandemic
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on the impact COVID-19 has had on two of the Company’s clinical studies in cystic fibrosis (CF). Due to the
Agilent Technologies to Change Location of Annual Meeting
Agilent Technologies, Inc. (NYSE: A) today filed a supplement to its proxy statement with the Securities and Exchange Commission announcing a change of location for its previously adjourned annual
LivaNova to Host Conference Call for First Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m
Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development With Digital Pathology
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex, a leader in preclinical digital pathology software-as-a-service.
Agilent Announces New Class 1 Triple Quadrupole LC/MS System
Agilent Technologies Inc. (NYSE: A) today introduced the Agilent K6460S Clinical Edition TQ LC/MS system, designed to improve in vitro diagnostic workflows in clinical labs.
Agilent’s
NanoRepro: Jetzt ist Vorsicht geboten!
Die Kapitalerhöhung des Medizintest-Unternehmens NanoRepro (WKN: 657710) konnte im aktuellen Corona-Hype voll platziert werden. Die großen Kursgewinne sind jetzt aber nicht mehr zu erwarten
IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations
IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the
Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact
Pfizer Inc. (NYSE: PFE) today announced the completion of a $1.25 billion ten-year “sustainability” bond paying interest semi-annually of 2.625 percent and maturing April 1, 2030. This is Pfizer’s
Drägerwerk: Aktie dank Nachfrageboom im Höhenflug
Drägerwerk (WKN: 555060) erlebt eine Sonderkonjunktur durch die weltweite Ausbreitung des Coronavirus. Die Aktie klettert heute +8,01% auf 95,75 Euro.
Dass die Medizinprodukte jetzt „mehr gebraucht
NanoRepro: Corona-Test als Rettung?
Spekulanten stürzen sich seit einiger Zeit auf Papiere des Medizintest-Unternehmens NanoRepro (WKN: 657710). Sie hoffen auf den großen Wurf durch den Vertriebsstart eines Corona-Tests – und
Gemeinsamer Bundesausschuss beschließt Aufnahme von TTFields in die Richtlinie Methoden Vertragsärztlicher Versorgung (MVV-RL)
Novocure (NASDAQ: NVCR) gab heute bekannt, dass der Gemeinsame Bundesausschuss (G-BA) die Ergänzung der MVV-RL um die Methode Tumortherapiefelder (TTFields) beschlossen hat. Optune ist somit für
Simulations Plus Offers Rapid Response COVID-19 Research Initiative
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the
Humana Works to Increase Capacity for Coronavirus Treatment
To prepare for the influx of patients who will need to be treated for coronavirus (COVID-19), Humana Inc. (NYSE: HUM) is taking steps to make it easier for members and health systems. Specifically
LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart